Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac762 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von David S McLaren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UK. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UK.
- Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK.
ORCID-Profile: Robert D Murray
Zitieren
APA
McLaren, D. S., & Murray, R. D. (2023). Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac762
Vancouver
McLaren DS, Murray RD. Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac762
BibTeX
@article{McLaren2023,
author = {McLaren, David S and Murray, Robert D},
title = {Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac762}
}
EUVIMED